Background
Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors.• Towards understanding the mechanisms of actions of carcinoembryonic antigen-related cell adhesion molecule 6 in cancer progression., PMID:29110374• Analysis of heterophilic cell adhesion mediated by CD66b and CD66c using their soluble recombinant proteins., PMID:8645267• Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen)., PMID:16204051• Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas., PMID:10666389• [Nonspecific cross-reacting antigen (NCA)]., PMID:16149618• Purification and characterization of a 95-kDa protein--carcinoembryonic antigen-related cell adhesion molecule 8--from normal human granulocytes., PMID:12379336• The KOR-SA3544 antigen predominantly expressed on the surface of Philadelphia chromosome-positive acute lymphoblastic leukemia cells is nonspecific cross-reacting antigen-50/90 (CD66c) and invariably expressed in cytoplasm of human leukemia cells., PMID:10374883• Immunochemical analysis of carcinoembryonic antigen (CEA)-related antigens differentially localized in intracellular granules of human neutrophils., PMID:8543346• Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers., PMID:17201906• Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses., PMID:23806607